Beginning Wednesday, Santa Ana winds are returning to the Southland�prompting a warning for extreme fire danger.... Read more.

Waste management industry news, voices and jobs for professionals. Optimized for your mobile phone.... Read more.

SPOKANE, Wash. � With the Thanksgiving travel season wrapped up and everyone heading home, TSA is working right now to address the influx of passengers and keep them safe. TSA is reporting that 9.5 million passengers traveled over the 10 day time period of Thanksgiving. That might sound like a lot, but it�s actually in stark contrast with what we are used to during this time frame. Daily travel numbers have been under 1 million travelers since around April 14, only going up above 1 million a handful of times. TSA said right now, as all of those people are heading home, they have aggressively installed equipment that improves both the security and efficiency of screening operations to contain the spread of COVID-19. They have added acrylic barriers at various points throughout the checkpoint, new credential authentication technology and new computed scanners that replace existing x-ray technology. On Monday, TSA reported 981,000 travelers. FOX28 Spokane�... Read more.

SAFETY in sport is paramount and any footballer with concussion symptoms should sit out immediately, the JFA development manager has said.... Read more.

SABETHA, KAN. � Extru-Tech, Inc., a leader in extrusion and drying technology, recently announced an upgrade to its vertical cooler, which focuses on the addition of an Advanced Feature Sanitary Cone to improve food safety, cleanability, product consistency and production efficiency. The new feature is similar in design to the sanitary cone used in Extru-Tech�s next-generation Advanced Feature Vertical Cooler, according to Norm Schmitt, corporate sales manager at Extru-Tech. �In this case, though, the Advanced Feature Sanitary Cone was designed to replace both the internal . . .... Read more.

Pharmacists' expertise crucial in success of virus jabs but safety of staff and patients paramount: RPS - Latest Pharmacy News | Business | Magazine - Pharmacy Business... Read more.

Holiday Haven returns with health and safety a priority - - Champion... Read more.

Hours after United Kingdom approved Pfizer coronavirus vaccine for emergency use, UK's country medicine regulator MHRA chief Dr June Raine spoke about the safety of the vaccine amid other concerns.... Read more.

GE Hitachi Nuclear small modular nuclear reactor gains early NRC safety approval - Power Engineering Magazine... Read more.

Online shopping can be convenient, cost-effective and safe, provided folks take certain precautions before making purchases.... Read more.

Speaker DeLeo outlines new safety protocols... Read more.

The all-new fifth-generation Volkswagen Caddy will land in Australia in the second half of next year, welcoming a new passenger and commercial vehicle range now underpinned by the brand�s MQB Platform shared with the eighth-generation Golf.... Read more.

The 'safety bubble' is in the form of a plastic canopy that would minimise physical contact during the delivery process.... Read more.

Rapid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 monthsRapid and substantial improvement in functioning achieved by 55% of patients at 2 weeks, 71% at 6 weeks (Sheehan Disability Scale), and sustained over 12 monthsMarked or moderate improvement in depression achieved by 50% of patients at 2 weeks, 83% at 6 weeks (Clinical Global Impression), and sustained over 12 monthsEfficacy in patients failing one prior antidepressant similar to overall results Long-term safety profile consistent with previously completed controlled trials, with no new safety signals detectedNDA on track for submission in January 2021NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced positive results from the long-term, open-label Phase 3 COMET trial of AXS-05 in patients with major depressive disorder (MDD), and the open-label Phase 2 COMET-AU trial in patients failing one prior antidepressant treatment. AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity. Patients treated with AXS-05 in these trials experienced rapid, substantial, and durable improvements in depressive symptoms and functional impairment that was sustained over the 12-month treatment period. AXS-05 was well tolerated over the long-term treatment period with a safety profile consistent with what was observed in the previously reported controlled trials in terms of frequency and type of adverse events, with no new safety signals detected. Axsome remains on track to submit an NDA for AXS-05 in the treatment of MDD in January 2021.“The data from the open-label Phase 3 COMET trial indicate that AXS-05 treatment is associated with rapid improvement in both depressive symptoms and related functional impairment that are sustained with long-term treatment and accompanied by a favorable safety profile,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Results from the open-label Phase 2 COMET-AU trial further indicate that the treatment benefits with AXS-05 were also substantial in patients who were unresponsive to a prior antidepressant. Overall, the short and long-term efficacy and safety data from these real-world studies add to the differentiated clinical profile of AXS-05, and are consistent with those observed in our previously reported double-blind efficacy trials.”The COMET (Clinical Outcomes with NMDA-based Depression Treatment) trial evaluated the efficacy and safety of AXS-05 (45 mg dextromethorphan-105 mg bupropion modulated delivery tablet) in patients with MDD who were treated twice daily for up to 12 months. A total of 876 patients were enrolled, consisting of 265 patients who rolled over from prior controlled trials with AXS-05 (roll-over patients), and 611 new (de novo) patients who had not previously participated in an AXS-05 trial. The trial was concluded once at least 300 patients had been treated for 6 months and approximately 100 patients had been treated for 12 months, as pre-specified. At the time of study conclusion, 597 patients had reached at least 6 months, and 110 patients had reached at least 12 months of treatment. The COMET-AU trial evaluated 115 patients with antidepressant unresponsive (AU) MDD, defined as patients with ongoing symptoms of depression despite previously receiving one standard antidepressant pharmacotherapy. Safety results discussed below include all patients enrolled in the COMET trial. Efficacy results from the overall COMET trial presented below are for de novo patients only (n=611). Maintenance of efficacy results for roll-over patients were similar, demonstrating sustained efficacy over 12 months, and will be presented in future scientific publications.In the overall COMET trial, AXS-05 treatment resulted in rapid, substantial, and durable improvement in depressive symptoms, measured using the Montgomery-Åsberg Depression Rating Scale (MADRS), which was sustained or increased with long-term treatment. Patients experienced mean reductions from baseline in the MADRS total score of 14.0 points at Week 2 and 21.1 points at Week 6 (primary timepoint). Reductions from baseline at 6 and 12 months were 23.9 points and 23.0 points, respectively.Clinical response on the MADRS (defined as ≥50% reduction from baseline) after treatment with AXS-05 was achieved by 39.7% of patients at Week 2 and 73.2% of patients at Week 6. This rate of response was sustained or increased with long-term treatment, with 84.6% and 82.8% of patients achieving a clinical response at 6 and 12 months, respectively. Remission from depression (defined as MADRS ≤10) after treatment with AXS-05 was achieved by 21.5% of patients at Week 2 and 52.5% of patients at Week 6. This rate of remission was sustained or increased with long-term treatment, with 68.7% and 69.0% of patients in remission at 6 and 12 months, respectively.Clinicians reported rapid, substantial, and durable global improvement in depressive symptoms, measured by the Clinical Global Impression of Improvement (CGI-I) scale, in patients treated with AXS-05. Marked or moderate improvement in depressive symptoms was achieved after treatment with AXS-05 by 50.4% of patients at Week 2 and 83.1% of patients at Week 6. This improvement on the CGI-I was sustained or increased with long-term treatment, as evidenced by marked or moderate improvement being achieved by 86.7% and 93.1% of patients at 6 and 12 months, respectively.Patients experienced rapid, substantial, and durable improvement in functional impairment, as measured by the Sheehan Disability Scale (SDS) with AXS-05 treatment. The SDS is a patient-rated scale that was designed to assess functioning in work, social life, and family life, and is among the most commonly used functional impairment scales in depression clinical trials. Clinical response on the SDS (defined as a total score of ≤12) was achieved after treatment with AXS-05 by 55.1% of patients at Week 2 and 70.7% of patients at Week 6. This improvement in functioning was maintained or increased with long-term treatment with AXS-05, as evidenced by clinical response on the SDS being achieved by 80.6% and 75.9% of patients at 6 months and at 12 months, respectively.Results of the COMET-AU trial were similar to those of the overall COMET study, demonstrating rapid, substantial, and durable improvements in depressive symptoms and functional impairment with AXS-05 treatment in patients who had failed one prior antidepressant treatment. Mean reductions from baseline in the MADRS total score were 13.1 points at Week 2 and 19.1 points at Week 6. Clinical response on the MADRS was achieved by 33.3% of patients at Week 2 and 64.6% of patients at Week 6. Remission from depression was achieved by 15.7% of patients at Week 2 and 40.4% of patients at Week 6. Marked or moderate improvement in depressive symptoms, assessed by the CGI-I scale, was achieved by 40.7% of patients at Week 2 and 70.0% of patients at Week 6. Clinical response on the SDS was achieved by 48.1% of patients at Week 2 and 63.4% of patients at Week 6. The improvements in depressive symptoms and functioning were sustained with long-term treatment.AXS-05 was well tolerated with long-term dosing. The safety profile of AXS-05 over the 12-month treatment period was consistent with what was previously reported in short-term controlled trials, with no new safety signals detected. The most commonly reported adverse events in the COMET trial were dizziness (12.7%), nausea (11.9%), headache (8.8%), dry mouth (7.1%), and decreased appetite (6.1%). These adverse events occurred at rates that were similar to those observed in the previously reported controlled trials with AXS-05. During the 12-month trial, 8.4% of patients discontinued due to adverse events, with no individual adverse event in more than 1.5% of patients. Treatment with AXS-05 was not associated with psychotomimetic effects, cognitive im... Read more.

December 2, 2020 - Commissioner Jessica Rosenworcel of the Federal Communications Commission � and who appears to be considered for elevation to chairman of the... Read more.

The New Jersey Department of Health issued guidelines for the winter holidays and celebrations.... Read more.

Changes to sprinkler regulations.... Read more.

New data show safety and efficacy of roxadustat in treating anemia secondary to lower-risk myelodysplastic syndromes (MDS) regardless of ring sideroblast...... Read more.

Latest added Single-Person Household Health Safety Service Market research study by MarketDigits offers detailed product outlook and elaborates market... Read more.

Health Secretary Matt Hancock discussed the prospect of a televised jab with broadcaster Piers Morgan.... Read more.

The Authority is responsible for administering the Nuclear Safety and Radiation Protection Act of 2015, a comprehensive act covering nuclear safety, security and safeguards, as well as civil liability for nuclear damage.... Read more.